The Mission Report


Biotechnology Industry Organization (BIO)
The 15th Annual BIO CEO & Investor Conference
February 11-12, 2013

Presenting Companies:

 

Aastrom Biosciences, Inc. (ASTM)

Aastrom Biosciences, Inc. (NASDAQ: ASTM) is the leading developer of patient-specific, expanded multicellular therapies for treating severe, chronic cardiovascular diseases. The company’s proprietary cell-processing technology enables the manufacturing of ixmyelocel-T, which is a patent-specific multicellular therapy expanded from a patient’s own bone marrow and then directly delivered to damaged tissues. The company has taken this therapy into late-stage clinical development, including a Phase 3 clinical program and a Phase 2b clinical trial. For more information, visit the company’s Web site at www.aastrom.com

ACADIA Pharmaceuticals, Inc. (ACAD)

ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD) is a biopharmaceutical company with its focus on innovative treatments addressing unmet medical needs in neurological and related central nervous system disorders. Pimavanserin, which is in Phase III clinical development as a potential first-in-class treatment for Parkinson’s disease psychosis, leads the company’s pipeline of product candidates. All the company’s product candidates are small molecules emanating from discoveries made at ACADIA. For more information, visit the company’s Web site at www.acadia-pharm.com

Advanced Cell Technology, Inc. (ACTC)

Advanced Cell Technology, Inc. (OTCBB: ACTC) is a biotechnology company focused on the application of cellular technology in the field of regenerative medicine. The company specializes in developing cellular therapies to treat diseases and conditions impacting tens of millions of people across the globe. ACT is a leader in the field of regenerative medicine, developing stem cell-based technologies – both adult and human embryonic – and other proprietary methods for patient-specific therapies. For more information, visit the company’s Web site at www.advancedcell.com

ADVENTRX Pharmaceuticals, Inc. (ANX)

ADVENTRX Pharmaceuticals, Inc. (NYSE MKT: ANX) is a biopharmaceutical company engaged in the development of proprietary product candidates for treating various diseases and conditions. ANX-188, the company’s lead product candidate, is initially being developed as a treatment for complications arising from sickle cell disease and has the potential to reduce ischemic tissue injury and end-organ damage by restoring microvascular function, which is compromised in various serious and life-threatening diseases and conditions. For more information, visit the company’s Web site at www.adventrx.com

Affymax, Inc. (AFFY)

Affymax, Inc. (NASDAQ: AFFY) is a Palo Alto, Calif.-based biopharmaceutical company. The company’s focus is on discovering, developing and delivering innovative therapies to improve the lives of patients suffering with kidney disease and other serious, often life-threatening illnesses. OMONTYS, the company’s first marketed products, was approved by the U.S. FDA in March 2012. For more information, visit the company’s Web site at www.affymax.com

Agenus, Inc. (AGEN)

Agenus, Inc. (NASDAQ: AGEN) is a biotechnology company engaged in developing treatments for cancers and infectious diseases. The company’s focus is on immunotherapeutic products based on strong platform technologies, with multiple product candidates advancing through the clinic, including a number of product candidates that have advanced into late-stage clinical trials through corporate partners. For more information, visit the company’s Web site at www.agenusbio.com

Alkermes plc (ALKS)

Alkermes plc (NASDAQ: ALKS) is a fully integrated, worldwide biopharmaceutical company focused on applying its scientific expertise and proprietary technologies in the development of innovative medicines to improve patient outcomes. Headquartered in Dublin, Ireland, the company has a diversified portfolio including more than 20 commercial drug products and an extensive clinical pipeline of product candidates that address central nervous system disorders like addiction, schizophrenia and depression. The company has an R&D center in Waltham, Mass.; a research and manufacturing facility in Athlone, Ireland; and manufacturing facilities in Gainesville, Ga., and Wilmington, Ohio. For more information, visit the company’s Web site at www.alkermes.com

Alnylam Pharmaceuticals, Inc. (ALNY)

Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is a biopharmaceutical company engaged in developing novel therapeutics based on RNA interference (RNAi). The company is at the helm of translating RNAi into a new class of innovative medicines, with a core focus on RNAi therapeutics for treating genetically defined diseases. As part of its “Alnylam 5x15” strategy, Alnylam plans to have five RNAi therapeutic products for genetically defined diseases in clinical development by the end of 2015. For more information, visit the company’s Web site at www.alnylam.com

Anthera Pharmaceuticals, Inc. (ANTH)

Anthera Pharmaceuticals, Inc. (NASDAQ: ANTH) is a biopharmaceutical company engaged in developing and commercializing products for the treatment of serious illnesses, such as cardiovascular and autoimmune diseases. The company’s clinical-stage program includes a Phase 2 study of blisibimod, which targets elevated B-lymphocyte stimulator (BLyS or BAFF) levels and has been associated with various B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. For more information, visit the company’s Web site at www.anthera.com

Antisense Therapeutics Ltd. (ATHJF)

Antisense Therapeutics Ltd. (OTC: ATHJF) is an Australian pharmaceutical drug discovery and development company focused on creating, developing and commercializing novel antisense therapeutics. The company’s strategy involves creating antisense drugs – in collaboration with technology and research partners – that address diseases for which there are large and/or poorly met markets; outsourcing preclinical and clinical testing of candidate drugs to expert contractors; and commercializing drugs with pre-clinical or clinical testing success through licensing deals or other partnerships with major pharmaceutical companies. For more information, visit the company’s Web site at www.antisense.com.au

Apricus Biosciences, Inc. (APRI)

Apricus Biosciences, Inc. (NASDAQ: APRI) is a biopharmaceutical company engaged in developing and marketing innovative treatments to help large patient populations across numerous high-demand therapeutic classes, including male and female sexual health. With three approved products, the company has additionally developed a strong pipeline of multiple late-stage product opportunities. Headquartered in San Diego, Calif., the company has commercial operations in both the U.S. and Europe. For more information, visit the company’s Web site at www.apricusbio.com

Aradigm Corp. (ARDM)

Aradigm Corp. (OTCBB: ARDM) is an emerging specialty pharmaceutical company engaged in developing and commercializing a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. The company’s product candidates address the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia, anthrax infections and smoking cessation. The company is actively focused on fulfilling its promise to develop inhalation drug products that can potentially revolutionize the quality of life for patients with severe pulmonary disease. For more information, visit the company’s Web site at www.aradigm.com

Arena Pharmaceuticals, Inc. (ARNA)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs for weight management, cardiovascular disease, inflammation and other disorders. The company’s internally discovered drug, BELVIQ (lorcaserin HCI), was approved by the U.S. FDA in June 2012 and is under review for regulatory approval in other jurisdictions. The company’s U.S. operations are located in San Diego, Calif., and its international operations – including its commercial manufacturing facility – are located in Zofingen, Switzerland. For more information, visit the company’s Web site at www.arenapharm.com

Astex Pharmaceuticals, Inc. (ASTX)

Astex Pharmaceuticals, Inc. (NASDAQ: ASTX) is a pharmaceutical company focused on the discovery and development of novel small molecule therapeutics, with a focus on oncology. The company is currently engaged in developing a proprietary pipeline of novel therapies and is creating de-risked products for partnership with leading pharmaceutical companies. The company developed Dacogen (decitabine) for injection and receives significant royalties for its worldwide sales. For more information, visit the company’s Web site at www.astx.com

Athersys, Inc. (ATHX)

Athersys, Inc. (NASDAQ: ATHX) is a clinical stage biopharmaceutical company focused on discovering and developing therapeutic product candidates for extending and enhancing human quality of life. The company is currently developing its MultiStem cell therapy product and has developed a diverse portfolio of other technologies and product development opportunities, as well as strategic partnerships and collaborations with leading biopharmaceutical companies and world-renowned research institutions. For more information, visit the company’s Web site at www.athersys.com

Atossa Genetics, Inc. (ATOS)

Atossa Genetics, Inc. (NASDAQ: ATOS), known as The Breast Health Company, is engaged in the prevention of breast cancer through commercializing patented, FDA-approved diagnostic medical devices and patented, laboratory-developed tests for detecting precursors to breast cancer up to eight years before mammography. The company is also focused on research and development efforts that may enable the commercialization of treatments for pre-cancerous lesions. Atossa Genetics is based in Seattle, Wash. For more information, visit the company’s Web site at www.atossagenetics.com

Biodel, Inc. (BIOD)

Biodel, Inc. (NASDAQ:BIOD) is a specialty pharmaceutical company that is engaged in the development and commercialization of innovative treatments for diabetes that are potentially safer, more effective and more convenient for diabetic patients. The company develops its product candidates by improving the therapeutic profiles of existing drugs through the application of proprietary formulation technologies. For more information, visit the company’s Web site at www.biodel.com

BioDelivery Sciences International, Inc. (BDSI)

BioDelivery Sciences International, Inc. (NASDAQ: BDSI) is a specialty pharmaceutical company leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics – either independently or in partnerships with third parties. The company is currently focused on developing products to meet unmet patient needs in pain management and addiction, and its pain franchise presently consists of two products utilizing the patented BEMA technology – ONSOLIS and BEMA Buprenorphine, both in Phase 3 clinical development. For more information, visit the company’s Web site at www.bdsi.com

BioLineRx Ltd. (BLRX)

BioLineRx Ltd. (NASDAQ: BLRX) is a biopharmaceutical development company focused on building a portfolio of products to address unmet medical needs or offer advantages over currently available therapies. The company’s portfolio presently consists of six clinical stage candidates, in addition to products in various pre-clinical development stages. The company’s business model is based on the acquisition of molecules, primarily from biotechnological incubators and academic institutions. For more information, visit the company’s Web site at www.biolinerx.com

Biotie Therapies Corp. (BIOZF)

Biotie Therapies Corp. (OTC: BIOZF) is a specialized drug development company engaged in the development of drugs to address diseases of high unmet medical need and significant market potential, including neurodegenerative and psychiatric disorders and inflammatory and fibrotic liver disease. The company’s development portfolio is strong and balanced, with several innovative small molecule and biological drug candidates at various stages of clinical development. For more information, visit the company’s Web site at www.biotie.com

Catalyst Pharmaceutical Partners, Inc. (CPRX)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX) is a development-stage specialty pharmaceutical company engaged in developing and commercializing prescription drugs that target orphan drug diseases as well as disorders of the central nervous system. The company currently has three products in development: Firdapse, planned for development to treat Lambert-Eaton Myasthenic Syndrome (LEMS); CPP-115, planned to be developed for treating epilepsy; and CPP-109, intended to be developed as a treatment for Tourette’s Disorder. For more information, visit the company’s Web site at www.catalystpharma.com

CEL-SCI Corp. (CVM)

CEL-SCI Corp. (NYSE MKT: CVM) is a biotechnology company engaged in research and development directed toward improving treatments for cancer and other diseases through utilization of the immune system – the body’s natural defense system. Multikine, the company’s lead investigational therapy, is being studied in a global Phase III clinical trial. Using its LEAPS technology program, CEL-SCI is additionally investigating an immunotherapy to potentially treat patients hospitalized with H1N1 and to serve as a vaccine for rheumatoid arthritis. For more information, visit the company’s Web site at www.cel-sci.com

Cempra, Inc. (CEMP)

Cempra, Inc. (NASDAQ: CEMP) is a clinical-stage pharmaceutical company engaged in developing antibiotics to meet critical needs in treating bacterial infectious diseases. The company’s two lead product candidates, solithromycin and CEM-102, are currently in advanced clinical development – both aimed at addressing the need for new treatments targeting drug-resistant bacterial infections. Cempra additionally plans to use its series of proprietary lead compounds from its novel macrolide library to treat chronic inflammatory diseases, endocrine diseases, gastric motility disorders and others. For more information, visit the company’s Web site at www.cempra.com

ChemoCentryx, Inc. (CCXI)

ChemoCentryx, Inc. (NASDAQ: CCXI) is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of orally administered therapeutics targeting the chemokine and chemoattractant systems to treat autoimmune diseases, inflammatory disorders and cancer. The company has generated multiple clinical and preclinical-stage programs – each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds – based on its proprietary drug discovery and drug development platform. For more information, visit the company’s Web site at www.chemocentryx.com

Cleveland BioLabs, Inc. (CBLI)

Cleveland BioLabs, Inc. (NASDAQ: CBLI) is a clinical-stage biotechnology company focused on leveraging deep mechanistic understanding of apoptosis – the cell death process – to develop a strong pipeline of compounds chiefly focused on oncology applications and mitigation of radiation injury. The company’s lead compound is currently being developed as both a radiation countermeasure and a cancer treatment. Cleveland BioLabs has two operating subsidiaries: Incuron LLC and Panacela Labs, Inc., as well as strategic relationships with various entities. For more information, visit the company’s Web site at www.cbiolabs.com

Cyclacel Pharmaceuticals, Inc. (CYCC)

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) is a biopharmaceutical company focused on developing oral therapies that target the various cell cycle control phases to treat cancer and other serious diseases. Sapacitabine, the company’s most advanced oral product candidate, is the subject of SEAMLESS – a Phase 3 clinical trial being conducted under an SPA with the FDA. The company’s pipeline also includes seliciclib and CYC065, both in various stages of development. For more information, visit the company’s Web site at www.cyclacel.com

Cytokinetics, Inc. (CYTK)

Cytokinetics, Inc. (NASDAQ: CYTK) is a clinical-stage biopharmaceutical company engaged in discovering and developing novel small molecule therapeutics that modulate muscle function to potentially treat serious diseases and medical conditions. The company has various drug candidates at different stages of clinical development, some in partnership with other companies, which have arisen from Cytokinetics’ muscle biology-focused research activities and are directed toward the cytoskeleton. For more information, visit the company’s Web site at www.cytokinetics.com

CytRx Corp. (CYTR)

CytRx Corp. (NASDAQ: CYTR) is a biopharmaceutical research and development company focused on oncology. The company’s oncology pipeline includes two programs, aldoxorubicin and tamibarotene, that are currently in clinical development for cancer indications. The company has also completed its evaluation of a third drug candidate, bafetinib, in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia and intends to seek a partner for further development. For more information, visit the company’s Web site at www.cytrx.com

DARA BioSciences, Inc. (DARA)

DARA BioSciences, Inc. (NASDAQ: DARA) is a specialty pharmaceutical company engaged in developing and commercializing oncology treatment and supportive care products. Through agreements with various entities, the company has comprehensive commercial coverage across the national oncology market. DARA is part of an integrated national network with yearly sales of more than $1 billion in cancer therapeutics, and its distribution network consists of more than 45,000 retail pharmacies, mail order pharmacies and long-term care facilities. For more information, visit the company’s Web site at www.darabio.com

DiaMedica, Inc. (DMA)

DiaMedica, Inc. (TSX-V: DMA) is a biotechnology company engaged in the development of first-in-class treatments for diabetes. DM-199, the company’s lead compound, is a recombinant human protein for treating both Type 1 and Type 2 diabetes and their related complications. DiaMedica is also in the process of developing DM-204, the first therapeutic GPCR agonist monoclonal antibody for the treatment of Type 2 diabetes and cardiovascular disease. For more information, visit the company’s Web site at www.diamedica.com

DURECT Corp. (DRRX)

DURECT Corp. (NASDAQ: DRRX) is a specialty pharmaceutical company focused on developing innovative drugs for pain and chronic diseases, with late-stage development programs including REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil. The company’s proprietary oral, transdermal and injectable depot delivery technologies facilitate new indications and superior clinical/commercial attributes, including abuse deterrence and improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, visit the company’s Web site at www.durect.com

EpiCept Corp. (EPCT)

EpiCept Corp. (OTCQX: EPCT) is a specialty pharmaceutical company focused on developing and commercializing pharmaceutical products to treat pain and cancer. The company’s cancer product, Ceplene, has been approved in the European Union, and its balanced pipeline of three major clinical product candidates includes AmiKet, Crolibulin and Azixa. EpiCept’s headquarters are located in Tarrytown, N.Y. For more information, visit the company’s Web site at www.epicept.com

Eternity Healthcare, Inc. (ETAH)

Eternity Healthcare, Inc. (OTCBB: ETAH) is a leading medical technology company in the United States. The company’s state-of-the-art medical devices include diagnostic kits, digital cholesterol readers, injection-free needles and many others. The company’s products are sold throughout the world to consumers and to healthcare professionals for use in physicians’ offices and pharmacies. For more information, visit the company’s Web site at www.eternityhealthcare.com

Exelixis, Inc. (EXEL)

Exelixis, Inc. (NASDAQ: EXEL) is a biotechnology company focused on the development of small molecule therapies to treat cancer. The company’s proprietary resources and development efforts are focused exclusively on COMETRIQ, its lead product. The company has additionally established a portfolio of other novel compounds believed to have the potential to address serious unmet medical needs – many of which are being advanced through collaborations with partners. For more information, visit the company’s Web site at www.exelixis.com

Furiex Pharmaceuticals, Inc. (FURX)

Furiex Pharmaceuticals, Inc. (NASDAQ: FURX) is a drug development collaboration company using innovative clinical development design to accelerate and increase the value of drug development programs, cost-efficiently advancing them through the drug discovery and development process. The company’s drug development programs are designed and driven by a core team with extensive experience in drug development. Furiex collaborates with pharmaceutical and biotechnology companies and has a diversified product portfolio and pipeline with multiple therapeutic candidates. For more information, visit the company’s Web site at www.furiex.com

Galena Biopharma, Inc. (GALE)

Galena Biopharma, Inc. (NASDAQ: GALE) is a biotechnology company engaged in developing innovative, targeted oncology treatments that address significant unmet medical needs to advance cancer care. The company’s current product pipeline includes NeuVax (nelipepimut-S or E75), which has been granted Special Protocol Assessment (SPA) from the FDA for a Phase III clinical trial, and Folate Binding Protein-E39 (FBP), which is a targeted vaccine aimed at preventing the recurrence of ovarian, endometrial and breast cancers. For more information, visit the company’s Web site at www.galenabiopharma.com

GENFIT (ALGFT)

GENFIT (Alternext: ALGFT) is a biopharmaceutical company at the forefront of drug discovery and development. The company’s focus is on the early diagnosis and preventive treatment of cardiometabolic and associated disorders. GENFIT’s mission is bringing therapeutic and diagnostic solutions to the pharmaceutical industry that can combat the major health concerns of diabetes, as well as its associated risk factors and complications. For more information, visit the company’s Web site at www.genfit.com

GeoVax Labs, Inc. (GOVX)

GeoVax Labs, Inc. (OTCQB: GOVX) is a biotechnology company focused on the development of vaccines for diseases caused by HIV. The company’s vaccines are unique in expressing virus-like particles displaying the trimeric membrane-bound form of the HIV-1 envelope glycoprotein. Presently in Phase I testing, the company’s second-generation preventive vaccine is planned to progress to Phase 2 efficacy testing. In various doses and combinations, GeoVax’s vaccine has been tested in around 500 people. For more information, visit the company’s Web site at www.geovax.com

GTx, Inc. (GTXI)

GTx, Inc. (NASDAQ: GTXI) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for treating cancer, for cancer supportive care and for other serious medical conditions. The company’s most advanced drug discovery and development programs are targeted at small molecules that selectively modulate the effects of estrogens and androgens. The company’s headquarters are located in Memphis, Tenn. For more information, visit the company’s Web site at www.gtxinc.com

Horizon Pharma, Inc. (HZNP)

Horizon Pharma, Inc. (NASDAQ: HZNP) is a biopharmaceutical company focused on the development and commercialization of innovative medicines to target unmet therapeutic needs in the areas of arthritis, pain and inflammatory diseases. The company’s strategy involves commercializing its products in the United States, exploring co-promotion for its DUEXIS novel tablet formulation (approved by the U.S. FDA in 2011), and entering into licensing or additional distribution agreements for commercialization of its products outside the United States. For more information, visit the company’s Web site at www.horizonpharma.com

iCo Therapeutics, Inc. (ICO)

iCo Therapeutics, Inc. (TSX-V: ICO) is a re-profiling company engaged in re-dosing or reformulating drugs with clinical history for new or expanded indications. The company owns the global rights to three products: iCo-007, currently in a Phase I trial in diabetic macular edema patients; iCo-008, a human monoclonal antibody against eotaxin-1 with Phase II clinical history; and iCo-009, an oral reformulation of a generic antifungal and anti-parasitic intravenous drug that, to date, has shown positive preclinical results. For more information, visit the company’s Web site at www.icotherapeutics.com

Idenix Pharmaceuticals, Inc. (IDIX)

Idenix Pharmaceuticals, Inc. (NASDAQ: IDIX) is a biopharmaceutical company dedicated to the discovery and development of drugs for the treatment of human viral diseases. The company’s focus is currently on treating patients with hepatitis C infection. Building on its expertise in nucleoside chemistry and other small molecule chemistry and biology, Idenix is poised to become a leader in antiviral pharmaceuticals. The company’s headquarters are located in Cambridge, Mass. For more information, visit the company’s Web site at www.idenix.com

Idera Pharmaceuticals, Inc. (IDRA)

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) is focused on applying its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates. The company has a clinical development program in autoimmune diseases as well as a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. Idera is exploring its gene-silencing oligonucleotide technology for inhibiting the expression of disease-promoting genes. For more information, visit the company’s Web site at www.iderapharma.com

ImmunoCellular Therapeutics Ltd. (IMUC)

ImmunoCellular Therapeutics Ltd. (NYSE MKT: IMUC) is a clinical-stage company focused on the development of immune-based therapies for treating brain and other cancers. The company is conducting a Phase II trial of its lead product candidate ICT-107, which is a dendritic cell-based vaccine targeting multiple tumor-associated antigens for glioblastoma. The company’s pipeline also includes ICT-121, a dendritic cell vaccine targeting CD133, and ICT-140, a dendritic cell vaccine targeting ovarian cancer antigens and cancer stem cells. For more information, visit the company’s Web site at www.imuc.com

ImmunoGen, Inc. (IMGN)

ImmunoGen, Inc. (NASDAQ: IMGN) is a biotechnology company developing targeted anticancer therapeutics using its Targeted Antibody Payload (TAP) technology, coupled with its expertise in monoclonal antibodies and tumor biology. A TAP compound delivers one of ImmunoGen’s purpose-developed cancer-killing agents specifically to tumor cells using a tumor-targeting monoclonal antibody. Ten different TAP compounds are currently in clinical testing – three of which are wholly owned by ImmunoGen. For more information, visit the company’s Web site at www.immunogen.com

Immunovaccine, Inc. (IMV)

Immunovaccine, Inc. (TSX-V: IMV) is a clinical-stage vaccine development company focused on the advancement of its patented DepoVax vaccine adjuvanting platform and product candidates for cancer therapy, infectious disease and animal health. Demonstrating safety and immunogenicity potential, Immunovaccine has advanced its platform technology and proprietary cancer vaccines into Phase I human clinical trials. The company is also advancing a broad infectious disease pipeline that includes vaccines for malaria, RSV and anthrax, and a collaborative anti-cocaine vaccine program. For more information, visit the company’s Web site at www.imvaccine.com

Inovio Pharmaceuticals, Inc. (INO)

Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) is revolutionizing vaccines for the prevention and treatment of today’s cancers and infectious diseases. The company’s SynCon vaccines are designed to provide universal cross-strain protection against both known and newly emergent unmatched strains of pathogens, such as influenza. Combined with Inovio’s proprietary electroporation delivery, these synthetic vaccines have been shown to generate best-in-class immune responses with a favorable safety profile. For more information, visit the company’s Web site at www.inovio.com

Intercept Pharmaceuticals, Inc. (ICPT)

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) is a clinical-stage biopharmaceutical company utilizing its expertise in bile acid chemistry to develop and commercialize novel therapeutics for the treatment of orphan and more prevalent liver diseases. OCA (obeticholic acid), the company’s lead product candidate, is initially being developed for the second-line treatment of primary biliary cirrhosis in patients with an inadequate response to, or intolerance for, ursodiol, which is currently the only approved therapy for this indication. For more information, visit the company’s Web site at www.interceptpharma.com

Lexicon Pharmaceuticals, Inc. (LXRX)

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) is a biopharmaceutical company engaged in the discovery of breakthrough treatments for human disease. Currently, the company has four drug programs in mid-stage development for diabetes, irritable bowel syndrome, carcinoid syndrome and rheumatoid arthritis. The company has identified more than 100 promising drug targets using its proprietary gene knockout technology, focusing drug discovery efforts on these targets to create an extensive pipeline of clinical and preclinical programs. For more information, visit the company’s Web site at www.lexpharma.com

NanoViricides, Inc. (NNVC)

NanoViricides, Inc. (OTCBB: NNVC) is a development-stage company engaged in creating special purpose nanomaterials for antiviral therapy. The company’s novel nanoviricide class of drug candidates is designed for the specific purpose of attacking and dismantling enveloped virus particles. NanoViricides is developing drugs against various viral diseases, including H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, oral and genital herpes (HSV), viral diseases of the eye, Ebola virus and others. For more information, visit the company’s Web site at www.nanoviricides.com

Navidea Biopharmaceuticals, Inc. (NAVB)

Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company engaged in developing and commercializing precision diagnostics and radiopharmaceutical agents. The company is actively developing four radiopharmaceutical agent platforms: Lymphoseek, NAV4694, NAV5001 and RIGScan. The company aims to deliver superior growth and shareholder return by bringing novel radiopharmaceutical agents to market and by advancing its pipeline through selective acquisitions, worldwide partnering and commercialization efforts. For more information, visit the company’s Web site at www.navidea.com

NeoStem, Inc. (NBS)

NeoStem, Inc. (NYSE MKT: NBS) is focused on developing and building on its core capabilities in cell therapy, to capitalize on the burgeoning cell therapy industry as well as cell therapy’s future role in the fight against chronic disease; the company also desires to aid in lessening the economic burden these diseases pose. NeoStem’s mission is to become a premier cell therapy company. For more information, visit the company’s Web site at www.neostem.com

Neuralstem, Inc. (CUR)

Neuralstem, Inc. (NYSE MKT: CUR) possesses patented technology that enables the production of neural stem cells of the human brain and spinal cord in commercial quantities, as well as the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company has been awarded orphan status designation by the FDA for its amyotrophic lateral sclerosis (ALS) cell therapy. Neuralstem also has product candidates currently undergoing trials. For more information, visit the company’s Web site at www.neuralstem.com

Newron Pharmaceuticals S.p.A. (NWPHF)

Newron Pharmaceuticals S.p.A. (OTC: NWPHF) is a biopharmaceutical company with its focus on novel therapies for central nervous system diseases and pain. Currently, Phase III trials of safinamide are ongoing for the treatment of Parkinson’s disease, which Merck Serono has exclusive global rights to develop, manufacture and commercialize. Newron is also evaluating the further clinical development of ralfinamide for pain and psychiatric diseases and has other projects at various stages of preclinical and clinical development. For more information, visit the company’s Web site at www.newron.com

NovaBay Pharmaceuticals, Inc. (NBY)

NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY) is a biotechnology company engaged in using its two distinct categories of product offerings – Aganocides and NeutroPhase Skin and Wound Cleanser – to address the large, unmet therapeutic needs of the worldwide anti-infective market. The company has four core business units that are developing treatments to tackle infections in the dermatology, urology, ophthalmology and wound care areas: DermaBay, UroBay, EyeBay and MediBay. For more information, visit the company’s Web site at www.novabaypharma.com

Novavax, Inc. (NVAX)

Novavax, Inc. (NASDAQ: NVAX) is a global clinical-stage biopharmaceutical company engaged in creating vaccines to address a wide range of infectious diseases throughout the world. Using innovative technology and new efficient manufacturing approaches, Novavax produces potent vaccine candidates with the goal of enabling countries to be well-prepared for and more effectively responsive to rapidly spreading infections. Committed to using its technology platforms to create location-specific vaccine solutions, Novavax is involved in a number of international partnerships. For more information, visit the company’s Web site at www.novavax.com

Novelos Therapeutics, Inc. (NVLT)

Novelos Therapeutics, Inc. (OTCQX: NVLT) is a pharmaceutical company engaged in the development of novel drugs to treat and diagnose cancer. The company’s cancer-targeted compounds are selectively taken up and retained in cancer cells – including cancer stem cells versus normal cells. Novelos’ therapeutic compounds, therefore, appear to directly kill cancer cells while reducing the harm to normal cells, potentially providing efficacy versus the three primary drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse. For more information, visit the company’s Web site at www.novelos.com

NPS Pharmaceuticals, Inc. (NPSP)

NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is a biopharmaceutical company engaged in bringing orphan products to patients who have rare disorders and few, if any, therapeutic options. The FDA-approved Gattex 0.05 mg/kg/d for subcutaneous injection is the company’s lead product. In addition to its proprietary programs, NPS has a royalty-based portfolio of products and product candidates which includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin and Takeda GmbH. For more information, visit the company’s Web site at www.npsp.com

Nymox Pharmaceutical Corp. (NYMX)

Nymox Pharmaceutical Corp. (NASDAQ: NYMX) is focused on researching and developing novel drugs and diagnostic products for the aging population. NX-1207, the company’s lead drug candidate, is a proprietary treatment for enlarged prostate or benign prostatic hyperplasia (BPH) that is currently in Phase 3 trials in the U.S. The company also has other new developing drug products in such areas as cancer, infectious disease and neurodegenerative diseases. For more information, visit the company’s Web site at www.nymox.com

Oculus Innovative Sciences, Inc. (OCLS)

Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) is a commercial healthcare company focused on designing, producing and marketing drugs, devices and nutritional products that are innovative, safe and effective. The company is engaged in pioneering innovative solutions in multiple markets, including dermatology, surgical, wound care and animal healthcare, and has commercialized products in the U.S., Europe, India, China, Mexico and select Middle East countries. For more information, visit the company’s Web site at www.oculusis.com

Ohr Pharmaceutical, Inc. (OHRP)

Ohr Pharmaceutical, Inc. (OTCQB: OHRP) is a pharmaceutical company focused on the clinical development of new drugs to address underserved therapeutic needs in markets that are large and growing. The company is currently focused on two lead compounds: Squalamine Eye Drops for treating the wet form of age-related macular degeneration, and OHR/AVR118 for treating cancer cachexia – both of which are currently being investigated in clinical Phase II trials. For more information, visit the company’s Web site at www.ohrpharmaceutical.com

OncoGenex Pharmaceuticals, Inc. (OGXI)

OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) is a biopharmaceutical company dedicated to developing and commercializing new therapies to address treatment resistance in cancer patients. Each product candidate in the company’s diverse oncology pipeline has a distinct mechanism of action and represents a unique opportunity for cancer drug development. OncoGenex has entered into a worldwide collaboration and license agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize custirsen, OncoGenex’s lead drug candidate. For more information, visit the company’s Web site at www.oncogenex.com

Oncolytics Biotech, Inc. (ONCY)

Oncolytics Biotech, Inc. (NASDAQ: ONCY) is a biotechnology company engaged in developing oncolytic viruses as potential therapeutics for cancer. Based in Calgary, Canada, the company has a clinical program that includes various human trials, such as a Phase III trial using REOLYSIN, its proprietary human reovirus formulation, in head and neck cancers. For more information, visit the company’s Web site at www.oncolyticsbiotech.com

OncoSec Medical, Inc. (ONCS)

OncoSec Medical, Inc. (OTCBB: ONCS) is a biopharmaceutical company focused on developing its advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy for treating solid tumor cancers. The company has based its core technology on its proprietary use of an electroporation platform that dramatically enhances delivery and uptake of a locally delivered DNA-based immunocytokine (ImmunoPulse) or chemotherapeutic agent (NeoPulse). Treating solid cancers with these targeted anti-cancer agents has resulted in selective destruction of cancerous cells while sparing healthy normal tissues. For more information, visit the company’s Web site at www.oncosec.com

Opexa Therapeutics, Inc. (OPXA)

Opexa Therapeutics, Inc. (NASDAQ: OPXA) is a biotechnology company focused on developing patient-specific cellular therapies for treating autoimmune diseases like MS. Tcelna, the company’s leading therapy, is a personalized cellular immunotherapy treatment currently in clinical development to target both SP-MS and Relapsing Remitting MS. Tcelna is derived from T-cells that have been isolated from peripheral blood, expanded ex vivo and reintroduced into patients through subcutaneous injections. For more information, visit the company’s Web site at www.opexatherapeutics.com

Oragenics, Inc. (OGEN)

Oragenics, Inc. (OTCQB: OGEN) is dedicated to becoming a global leader in probiotics for oral health in humans and pets and in novel antibiotics against infectious disease. The company is engaged in developing, marketing and selling proprietary probiotics under the brand names Evora and ProBiora, designed specifically for enhancing oral health for humans and pets. Oragenics has also established an exclusive worldwide channel collaboration for lantibiotics with Intrexon Corporation. For more information, visit the company’s Web site at www.oragenics.com

Orexigen Therapeutics, Inc. (OREX)

Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company, is focused on treating obesity. Contrave, Orexigen’s lead product candidate, has completed Phase III clinical trials, and a New Drug Application has been submitted and reviewed by the U.S. Food and Drug Administration. The company has additionally reached an agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, which is the Contrave cardiovascular outcomes trial. For more information, visit the company’s Web site at www.orexigen.com

OXiGENE, Inc. (OXGN)

OXiGENE, Inc. (NASDAQ: OXGN) is a clinical-stage biopharmaceutical company engaged in the development of novel therapeutics for treating cancer, with its primary focus on developing vascular disrupting agents that selectively disrupt abnormal blood vessels that are associated with solid tumor progression. The company is devoted to leveraging its intellectual property and therapeutic development expertise to provide patients with life-extending and life-enhancing medicines. For more information, visit the company’s Web site at www.oxigene.com

Palatin Technologies, Inc. (PTN)

Palatin Technologies, Inc. (NYSE MKT: PTN) is a biopharmaceutical company engaged in the development of targeted, receptor-specific peptide therapeutics for treating diseases that have significant unmet medical need but where there is also commercial potential. The company’s strategy involves developing products and then forming marketing collaborations with industry leaders to maximize the products’ commercial potential. For more information, visit the company’s Web site at www.palatin.com

POZEN, Inc. (POZN)

POZEN, Inc. (NASDAQ: POZN) is a progressive pharmaceutical company focused on transforming the way unmet medical needs are addressed by the healthcare industry. POZEN has successfully developed two self-invented products in two years, receiving FDA approval for both. Utilizing the funding from these milestone/royalty streams, the company is currently creating a portfolio of integrated aspirin therapies designed to reduce aspirin’s GI damage and enable its full power. For more information, visit the company’s Web site at www.pozen.com

Prima BioMed Ltd. (PBMD)

Prima BioMed Ltd. (NASDAQ: PBMD) is a biotechnology that is active throughout the world. A leader in personalized bio-therapeutic cancer products, the company is focused on leveraging its current technology and expertise in developing innovative treatment options for patients as well as maximizing shareholder value. CVac, the company’s lead product, is an autologous dendritic cell product presently in clinical trials for ovarian cancer patients in remission. For more information, visit the company’s Web site at www.primabiomed.com.au

ProMetic Life Sciences, Inc. (PLI)

ProMetic Life Sciences, Inc. (TSX: PLI) is a worldwide biopharmaceutical company that specializes in designing small molecules that mimic unique and specific interactions between proteins, research, development, manufacturing and marketing of various commercial applications derived from its proprietary Mimetic Ligand technology. The company uses this technology in the large-scale purification of biologics, in drug development, in proteomics and in eliminating pathogens. The company is also actively developing its own novel therapeutic products. For more information, visit the company’s Web site at www.prometic.com

Protalix BioTherapeutics, Inc. (PLX)

Protalix BioTherapeutics, Inc. (NYSE MKT: PLX) is a biopharmaceutical company engaged in developing and commercializing recombinant therapeutic proteins expressed through ProCellEx, a proprietary plant cell-based expression system. Using ProCellEx, the company is developing and commercializing a proprietary pipeline of novel and biosimilar proteins that target large, established pharmaceutical markets and rely on known biological action mechanisms. The company’s initial commercial focus is on complex therapeutic proteins to treat genetic disorders like Gaucher disease and Fabry disease. For more information, visit the company’s Web site at www.protalix.com

Provectus Pharmaceuticals, Inc. (PVCT)

Provectus Pharmaceuticals, Inc. (OTCQB: PVCT) is a biopharmaceutical company specializing in the development of oncology and dermatology therapies. PV-10, the company’s novel oncology drug, is designed to selectively target and destroy cancer cells without harming the surrounding healthy tissue. Provectus has received orphan drug designations from the FDA for its melanoma and hepatocellular carcinoma indications and recently completed Phase 2 trials of PV-10 as a metastatic melanoma therapy and PH-10 as a topical atopic dermatitis and psoriasis treatment. For more information, visit the company’s Web site at www.pvct.com

pSivida Corp. (PSDV)

pSivida Corp. (NASDAQ: PSDV) is engaged in developing tiny, sustained-release drug delivery products created to deliver drugs at a controlled or steady rate for months or years. The company is currently focused on treating chronic diseases of the back of the eye utilizing Durasert and BioSilicon, its core technology systems. pSivida’s headquarters are located in Watertown, Mass. For more information, visit the company’s Web site at www.psivida.com

Regulus Therapeutics, Inc. (RGLS)

Regulus Therapeutics, Inc. (NASDAQ: RGLS) is a biopharmaceutical company at the forefront of discovering and developing innovative medicines that target microRNAs. Leveraging a mature therapeutic platform that is based on technology developed over 20 years, the company is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. The company has strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi, as well as a research collaboration with Biogen Idec. For more information, visit the company’s Web site at www.regulusrx.com

ReNeuron Group Plc. (RENE)

ReNeuron Group Plc. (RENE.L) is a clinical-stage stem cell leader primarily focused on developing novel stem cell therapies to target areas of important unmet or inadequately met medical need. The company has used its stem cell technologies to develop cell-based therapies for significant disease conditions for which cells can be readily administered “off the shelf” to eligible patients without the need of additional immunosuppressive drug treatments. For more information, visit the company’s Web site at www.reneuron.com

Repros Therapeutics, Inc. (RPRX)

Repros Therapeutics, Inc. (NASDAQ: RPRX) is a development-stage biopharmaceutical company focused on developing oral small molecule drugs to address major unmet medical needs for male and female reproductive disorders. The company’s primary product candidate is Androxal, an orally active proprietary small molecule compound being developed for men of reproductive age with low testosterone levels. The company is also studying Proellex as a treatment for uterine fibroids in women. For more information, visit the company’s Web site at www.reprosrx.com

Resverlogix Corp. (RVX)

Resverlogix Corp. (TSX: RVX) is a clinical-stage cardiovascular company with an epigenetic platform technology that modulates protein production. The company is currently developing RVX-208, which is a first-in-class small molecule for treating atherosclerosis and the first BET bromodomain inhibitor in clinical trials. New compounds resulting from the company’s epigenetic drug discovery platform, which function by inhibiting BET bromodomains, have the potential to impact multiple diseases, including autoimmune diseases, cancer, neurodegenerative diseases and diabetes mellitus. For more information, visit the company’s Web site at www.resverlogix.com

Rigel Pharmaceuticals, Inc. (RIGL)

Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) is a clinical-stage drug development company engaged in the discovery and development of novel, small-molecule drugs to treat inflammatory and autoimmune diseases and muscle disorders. The company’s groundbreaking research is focused on intracellular signaling pathways and related targets that are critical to disease mechanisms, and Rigel’s productivity has brought about strategic collaborations with large pharmaceutical partners to develop and market its product candidates. For more information, visit the company’s Web site at www.rigel.com

RXi Pharmaceuticals Corp. (RXII)

RXi Pharmaceuticals Corp. (OTC: RXII) is a biotechnology company engaged in the discovery, development and commercialization of innovative therapies to address major unmet medical needs using RNA-targeted technologies. Building on the groundbreaking work of Nobel Laureate and RXi Scientific Advisory Board member Dr. Craig Mello, the company’s first product candidate, RXI-109, entered into human clinical development in June of 2012. For more information, visit the company’s Web site at www.rxipharma.com

SciClone Pharmaceuticals, Inc. (SCLN)

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) is a specialty pharmaceutical company with its primary focus in China. The company’s product portfolio includes therapies for oncology, infectious diseases and disorders of the cardiovascular, urological, respiratory and central nervous systems. Headquartered in Foster City, Calif., SciClone markets around 14 products in China and is also pursuing the registration of several other therapeutic products in that country. For more information, visit the company’s Web site at www.sciclone.com

Soligenix, Inc. (SNGX)

Soligenix, Inc. (OTCQB: SNGX) is a development-stage biopharmaceutical company engaged in developing products for the treatment of serious inflammatory diseases with unmet medical need. The company is developing several biodefense vaccines and therapeutics as well as proprietary formulations of oral BDP for the prevention and treatment of gastrointestinal disorders characterized by severe inflammation. Soligenix is also developing its novel innate defense regulator technology, SGX942, to treat oral mucositis. For more information, visit the company’s Web site at www.soligenix.com

StemCells, Inc. (STEM)

StemCells, Inc. (NASDAQ: STEM) is a leading developer of cell-based therapeutics and tools for stem cell-based research and drug discovery. StemCells’ lead therapeutic product candidate, HuCNS-SC cells, is currently being developed as a potential treatment for various central nervous system disorders. The company markets stem cell research products, including media and reagents, under the SC Proven brand. For more information, visit the company’s Web site at www.stemcellsinc.com

Sucampo Pharmaceuticals, Inc. (SCMP)

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) is a worldwide pharmaceutical company engaged in the innovative research, discovery, development and commercialization of proprietary drugs based on prostones. Sucampo Chairman, CEO and Co-founder Ryuji Ueno, M.D., Ph.D., was the first person to identify the therapeutic potential of prostones, which are naturally occurring fatty acid metabolites. Prostones have emerged as promising compounds with unique physiological activities and can be targeted for treating unmet or underserved medical needs. For more information, visit the company’s Web site at www.sucampo.com

Synthetic Biologics, Inc. (SYN)

Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company developing product candidates for serious infections and diseases. The company is developing a biologic for preventing C. diff infection as well as a series of monoclonal antibodies (mAbs) for treating serious infectious diseases. In collaboration with Intrexon, Synthetic Biologics is developing a synthetic DNA-based therapy for treating pulmonary arterial hypertension (PAH). The company is also developing treatments for relapsing-remitting multiple sclerosis, cognitive dysfunction in MS and amyotrophic lateral sclerosis. For more information, visit the company’s Web site at www.syntheticbiologics.com

Targacept, Inc. (TRGT)

Targacept, Inc. (NASDAQ: TRGT) is a clinical-stage biopharmaceutical company engaged in developing a varied pipeline of innovative NNR therapeutics for hard-to-treat nervous system diseases and disorders. The company’s clinical pipeline includes multiple Phase 2 product candidates that all represent first-in-class opportunities, and Targacept is leveraging its scientific leadership-diverse pipeline to attract noteworthy collaborations with worldwide pharmaceutical companies. For more information, visit the company’s at www.targacept.com

Tekmira Pharmaceuticals Corp. (TKMR)

Tekmira Pharmaceuticals Corp. (NASDAQ: TKMR) is a biopharmaceutical company and a leader in developing RNA interference (RNAi) therapeutics. The company is focused on advancing novel RNAi therapeutics and supplying pharmaceutical partners with its leading lipid nanoparticle delivery technology. Based in Vancouver, B.C., Tekmira has worked in the nucleic acid delivery field for more than a decade and has vast intellectual property covering LNPs. For more information, visit the company’s Web site at www.tekmirapharm.com

Tengion, Inc. (TNGN)

Tengion, Inc. (OTCQB: TNGN) is a leading clinical-stage regenerative medicine company focused on the development of its pioneering Organ Regeneration Platform. This platform is intended to harness the body’s intrinsic regenerative pathways to regenerate an array of native-like organs and tissues, with the aim of delaying or eliminating the need for chronic disease therapies, organ transplantation and anti-rejection medication. The company’s most advanced product candidate, the Neo-Urinary Conduit, is currently undergoing an initial clinical trial. For more information, visit the company’s Web site at www.tengion.com

TG Therapeutics, Inc. (TGTX)

TG Therapeutics, Inc. (OTCBB: TGTX) is a clinical-stage biopharmaceutical company engaged in acquiring, developing and commercializing pharmaceutical products that are medically important for the treatment of cancer and other underserved therapeutic needs. The company is currently developing two advanced therapies to target hematological malignancies, TG-1101 and TGR-1202. The company’s headquarters are located in New York City. For more information, visit the company’s Web site at www.tgtherapeutics.com

Tonix Pharmaceuticals Holding Corp. (TNXP)

Tonix Pharmaceuticals Holding Corp. (OTCQB: TNXP) is focused on the development of innovative prescription medicines for challenging disorders of the central nervous system. Tonix targets conditions characterized by significant unmet medical need, inadequate existing treatments and high patient and physician dissatisfaction. The company’s core technology improves sleep quality for patients suffering with chronic pain syndromes, which is thought to translate into a reduction of daytime pain and other symptoms. For more information, visit the company’s Web site at www.tonixpharma.com

Transcept Pharmaceuticals, Inc. (TSPT)

Transcept Pharmaceuticals, Inc. (NASDAQ: TSPT) is a specialty pharmaceutical company engaged in developing and commercializing proprietary products that address important therapeutic needs in the field of neuroscience. Intermezzo (zolpidem tartrate) sublingual tablet C-IV is the company’s first FDA-approved product. Commercialization and development rights for Intermezzo in the U.S. are held by Purdue Pharma. For more information, visit the company’s Web site at www.transcept.com

Transition Therapeutics, Inc. (TTHI)

Transition Therapeutics, Inc. (NASDAQ: TTHI) is a biopharmaceutical company focused on the development of novel therapeutics for disease indications with large markets. The company’s lead product, ELND005, is a treatment for Alzheimer’s disease and bipolar disorder. Transition additionally has an emerging pipeline of innovative preclinical and clinical drug candidates that includes drugs for anti-inflammatory and metabolic indications. For more information, visit the company’s Web site at www.transitiontherapeutics.com

Tranzyme Pharma, Inc. (TZYM)

Tranzyme Pharma, Inc. (NASDAQ: TZYM) is a biopharmaceutical company engaged in the discovery, development and commercialization of novel, mechanism-based therapeutics to treat upper gastrointestinal motility disorders. Though more than 40 percent of people in the U.S. are affected by these recurring conditions, only a limited number of safe and effective treatment options are available. Through leveraging MATCH, its proprietary drug discovery technology, Tranzyme is dedicated to pursuing first-in-class medicines to address areas with significant unmet medical need. For more information, visit the company’s Web site at www.tranzyme.com

Venaxis, Inc. (APPY)

Venaxis, Inc. (NASDAQ: APPY) is an in vitro diagnostic company pursuing clinical development and commercialization of APPY1, its blood-based appendicitis test. Designed to aid in identifying patients at low risk for acute appendicitis, thus enabling more conservative patient management, APPY1 is being initially developed for pediatric, adolescent and young adult patients with abdominal pain – this being the group with the highest risk for appendicitis and also the highest risk of long-term health effects from CT imaging. For more information, visit the company’s Web site at www.venaxis.com

Verastem, Inc. (VSTM)

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company engaged in discovering and developing drugs to treat cancer through targeted killing of cancer stem cells, which are an underlying cause of tumor recurrence and metastasis. The company is developing FAK, PI3K/mTOR and Wnt, which are small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation. For more information, visit the company’s Web site at www.verastem.com

VirtualScopics, Inc. (VSCP)

VirtualScopics, Inc. (NASDAQ: VSCP) is a leader in providing quantitative imaging solutions that accelerate drug and medical device development. The company has developed a robust software platform for analyzing and modeling both structural and functional medical images. In combination with VirtualScopics’ industry-leading expertise in advanced imaging biomarker measurement, this platform offers a clear window into the biological activity of drugs and devices in clinical trial patients – which allows sponsors to make better and faster decisions. For more information, visit the company’s Web site at www.virtualscopics.com

Zalicus, Inc. (ZLCS)

Zalicus, Inc. (NASDAQ: ZLCS) is a biopharmaceutical company engaged in discovering and developing novel treatments for patients suffering with pain. The company’s portfolio of proprietary clinical-stage product candidates has entered into various revenue-generating collaborations with large pharmaceutical companies relating to other products, product candidates and drug discovery technologies. Applying its expertise in discovering and developing selective ion channel modulators, as well as its combination high throughput screening capabilities, the company discovers innovative therapeutics for itself and its collaborators. For more information, visit the company’s Web site at www.zalicus.com

Zealand Pharma A/S (ZEAL)

Zealand Pharma A/S (NASDAQ OMX Copenhagen: ZEAL) is a Copenhagen, Denmark-based biotechnology company specializing in the discovery, optimization and development of novel peptide drugs. The company has an expansive and mature pipeline of drug candidates that have been identified through its own drug discovery activities. Zealand Pharma’s focus is in the field of diabetes/metabolic diseases, and its lead drug candidate, Lyxumia 1 (lixisenatide), is currently under regulatory review in various countries throughout the world. For more information, visit the company’s Web site at www.zealandpharma.com

ZIOPHARM Oncology, Inc. (ZIOP)

ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP) is a biopharmaceutical company engaged in developing and commercializing new cancer therapies. The company’s clinical programs include palifosfamide, currently being studied in two Phase 3 clinical trials; Ad-RTS IL-12, currently being tested in a Phase 2 clinical study; indibulin (ZIO-301), currently being studied in a Phase 1/2 trial; and darinaparsin (ZIO-101), currently part of ongoing studies with Solasia Pharma K.K. ZIOPHARM has operations in both Boston, Mass., and New York City. For more information, visit the company’s Web site at www.zionpharma.com

 
Twitter

For more frequent updates, follow us on Twitter!

Home     About Us     Blog     Investors     IR Services     Market Research     Partners     Contact     Disclaimer

© 2013 Mission Investor Relations. All rights reserved.
3645 Marketplace Blvd.   Suite 130-280   Atlanta, GA 30344   404-941-8975